The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?

CONCLUSION: SLNB changed the recommendation for/against chemotherapy, or the chemotherapy regiment recommended, in 4.8% of postmenopausal women with early-stage, ER-positive/HER2-negative breast cancer, and sonographically negative axilla when using RS > 25 or N2-3 disease as an indication for chemotherapy. Preoperative genomic profiling can guide de-escalation of axillary surgery.PMID:34006481 | DOI:10.1016/j.clbc.2021.02.011

Source: Clinical Genitourinary Cancer - May 19, 2021 Category: Cancer & Oncology Authors: Elaine Lee Carol Tweed Charles Mylander Laura Martino Martin Rosman Nicholas Huerta Kip Waite Lorraine Tafra Rubie Sue Jackson Source Type: research